Lynn Anne Bristol

Array ( [id] => 17905553 [patent_doc_number] => 11459397 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-04 [patent_title] => Self-crosslinking antibodies [patent_app_type] => utility [patent_app_number] => 16/068892 [patent_app_country] => US [patent_app_date] => 2017-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 18 [patent_no_of_words] => 63976 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 258 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13840651 [patent_doc_number] => 20190023810 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => BISPECIFIC ANTIBODIES HAVING CONSTANT REGION MUTATIONS AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 16/065917 [patent_app_country] => US [patent_app_date] => 2016-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733169 [patent_doc_number] => 20180371052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => CHIMERIC ANTIGEN RECEPTORS AND ENHANCEMENT OF ANTI-TUMOR ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/061987 [patent_app_country] => US [patent_app_date] => 2016-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16061987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622233 [patent_doc_number] => 20180362668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => HETERODIMER MOLECULE BASED ON CH3 DOMAIN, AND PREPARATION METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/062405 [patent_app_country] => US [patent_app_date] => 2016-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12167 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16062405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18085556 [patent_doc_number] => 11535674 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Bivalent bispecific antibody hybrid protein expression and preparation methods [patent_app_type] => utility [patent_app_number] => 16/079003 [patent_app_country] => US [patent_app_date] => 2016-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 21 [patent_no_of_words] => 14950 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 536 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16079003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929165 [patent_doc_number] => 20190048098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => BISPECIFIC ANTIBODY PLATFORM [patent_app_type] => utility [patent_app_number] => 16/061903 [patent_app_country] => US [patent_app_date] => 2016-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -154 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16061903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14611629 [patent_doc_number] => 10358500 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-23 [patent_title] => Humanized antibodies that bind LGR5 [patent_app_type] => utility [patent_app_number] => 15/379058 [patent_app_country] => US [patent_app_date] => 2016-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 24 [patent_no_of_words] => 19447 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15379058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13729815 [patent_doc_number] => 20180369375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS [patent_app_type] => utility [patent_app_number] => 16/062355 [patent_app_country] => US [patent_app_date] => 2016-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16062355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11979724 [patent_doc_number] => 20170283878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'MODULATION OF GLOBOSERIES GLYCOSPHINGOLIPID SYNTHESIS AND CANCER BIOMARKERS' [patent_app_type] => utility [patent_app_number] => 15/376598 [patent_app_country] => US [patent_app_date] => 2016-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 63196 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15376598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11555222 [patent_doc_number] => 20170101468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'HUMAN ANTI IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-LIFE AND THEIR USE IN TREATMENT OF ONCOLOGY, AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES' [patent_app_type] => utility [patent_app_number] => 15/368499 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 79828 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15368499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11513284 [patent_doc_number] => 20170080358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'Mutated Immunoglobulin-Binding Protein' [patent_app_type] => utility [patent_app_number] => 15/367640 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 10909 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15367640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590109 [patent_doc_number] => 20180346603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => MULTISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/779417 [patent_app_country] => US [patent_app_date] => 2016-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25090 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15779417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17014166 [patent_doc_number] => 11083785 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Siglec-10 antibodies [patent_app_type] => utility [patent_app_number] => 15/776452 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 5 [patent_no_of_words] => 24701 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13549021 [patent_doc_number] => 20180326058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => COMBINATION THERAPY USING T CELL REDIRECTION ANTIGEN BINDING MOLECULE AGAINST CELL HAVING IMMUNOSUPPRESSING FUNCTION [patent_app_type] => utility [patent_app_number] => 15/776587 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11956111 [patent_doc_number] => 20170260260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'Compositions and Methods for Antibodies Targeting Complement Protein C5' [patent_app_type] => utility [patent_app_number] => 15/354978 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 74 [patent_figures_cnt] => 74 [patent_no_of_words] => 49289 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15354978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17014166 [patent_doc_number] => 11083785 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Siglec-10 antibodies [patent_app_type] => utility [patent_app_number] => 15/776452 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 5 [patent_no_of_words] => 24701 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733177 [patent_doc_number] => 20180371056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => Multi-Span Chimeric Antigen Receptor [patent_app_type] => utility [patent_app_number] => 15/775541 [patent_app_country] => US [patent_app_date] => 2016-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15775541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551903 [patent_doc_number] => 20180327499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => ANTI- NKG2D SINGLE DOMAIN ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/775579 [patent_app_country] => US [patent_app_date] => 2016-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15775579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519611 [patent_doc_number] => 20180311348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => TRISPECIFIC MOLECULE COMBINING SPECIFIC TUMOR TARGETING AND LOCAL IMMUNE CHECKPOINT INHIBITION [patent_app_type] => utility [patent_app_number] => 15/764788 [patent_app_country] => US [patent_app_date] => 2016-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15764788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14145495 [patent_doc_number] => 10253106 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells [patent_app_type] => utility [patent_app_number] => 15/346332 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 13172 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15346332 [rel_patent_id] =>[rel_patent_doc_number] =>)